BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00252200
Recruitment Status : Completed
First Posted : November 11, 2005
Last Update Posted : September 23, 2009
Scios, Inc.
Information provided by:
Mayo Clinic

Brief Summary:
Use of BNP (nesiritide) vs placebo to help protect kidney function in patients undergoing heart bypass surgery.

Condition or disease Intervention/treatment Phase
Acute Kidney Failure Drug: Neseritide Phase 1 Phase 2

Detailed Description:
This is a randomized, double-blind, placebo controlled study of low dose nesiritide to prevent renal insufficiency after cardiopulmonary bypass surgery. Patients included are those with greater than mild renal insufficiency preoperatively as defined by having a creatinine clearance of less than 50 mL/minute determined by the Cockroft-Gault formula. The infusion of nesiritide (BNP) 0.005 mcg/Kg/minute or placebo begins 1 hour before surgery and runs for 24 hours started after the induction of anesthesia prior to cardiopulmonary bypass.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Low Dose Continuous Infusion of BNP (Nesiritide) in the Prevention of Renal Insufficiency Post Cardiopulmonary Bypass Cardiac Surgery.
Study Start Date : March 2003
Actual Primary Completion Date : October 2007
Actual Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Nesiritide
U.S. FDA Resources

Intervention Details:
    Drug: Neseritide
    Dose of Nesiritide infusion will be 0.005 ug/Kg/min
    Other Name: BNP, Nesiritide

Primary Outcome Measures :
  1. Creatinine Clearance at 72 hours determined by the Cockroft-Gault formula [ Time Frame: 72 hours post op ]

Secondary Outcome Measures :
  1. Number of patients requiring dialysis during the hospitalization [ Time Frame: before hospital discharge ]
  2. Plasma aldosterone levels at 12 hours and 24 hours [ Time Frame: 12 hours and 24 hours postoperatively ]
  3. Total time on ventilator, ICU length of stay, total length of stay in hospital [ Time Frame: total length of hospital stay ]
  4. pre and postoperative diuretic dose used [ Time Frame: pre operative and postoperate ]
  5. Need or absence of need for inotropic support in the 72 hour perioperative period [ Time Frame: 72 hours perioperative ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients > 18 years old, undergoing cardiac surgery requiring cardiopulmonary bypass with baseline creatinine clearance < 50 ml/min and who are not dialysis dependent.

Exclusion criteria:

  • Cardiogenic shock or hypotension with systolic BP < 90 mmHg.
  • Patients with acute or chronic aortic dissection.
  • Patients who are enrolled in other studies that have an effect the renal function.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00252200

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Scios, Inc.
Principal Investigator: Horng H. Chen, M.D. Mayo Clinic

Responsible Party: Horng H. Chen, Mayo Clinic Rochester Identifier: NCT00252200     History of Changes
Other Study ID Numbers: 621-03
First Posted: November 11, 2005    Key Record Dates
Last Update Posted: September 23, 2009
Last Verified: September 2009

Additional relevant MeSH terms:
Renal Insufficiency
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
Natriuretic Peptide, Brain
Natriuretic Agents
Physiological Effects of Drugs